Among 16 MSI-H/dMMR patients, the PTCH1 mutation was also associated with improved OS ( P = 0.0607, HR, 0.149, 95% CI, 0.020–1.090) and PFS ( P = 0.057, HR, 0.178, 95% CI, 0.030–1.055) compared with PTCH1 wild-type patients, although with marginal significance (Supplementary Fig.
← all excerpts
PTCH1 mutation promotes antitumor immunity and the response to immune checkpoint inhibitors in colorectal cancer patients.
1
—
—